QIAGEN Advances Precision Medicine by Automating Guidelines on Cancer Variants in Industry-leading QIAGEN Clinical Insight So...
November 15 2017 - 4:05PM
PR Newswire (US)
HILDEN, Germany, and GERMANTOWN, Maryland, November 15, 2017 /PRNewswire/ --
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today
launched enhancements in its QIAGEN Clinical Insight (QCI)
bioinformatics software automating the AMP/ASCO/CAP Standards
and Guidelines for the Interpretation and Reporting of Sequence
Variants in Cancer, advancing precision medicine with the first
solution to offer molecular pathologists critical information
needed to guide oncologists' treatment decisions. Leading oncology
and pathology groups published the guidelines in January 20171 in response to growing
clinical implementation of next-generation sequencing (NGS) for
genetic profiling of cancers. QIAGEN's QCI-Interpret software
integrates the consensus standards with a comprehensive biomedical
knowledge base on potential treatments and clinical trials, guiding
the selection of treatments based on the findings from each
patient's genomic testing and diagnosis. QIAGEN is launching the
QCI enhancements this week at the Association for Molecular
Pathology (AMP) 2017 Annual Meeting in Salt Lake City, Utah.
Click here for the full press release
https://corporate.qiagen.com/newsroom/press-releases/2017/2017-11-15-QCI_AMP?sc_lang=en
Contacts:
QIAGEN
Investor Relations
John Gilardi
+49-2103-29-11711
e-mail: ir@QIAGEN.com
Public Relations
Dr. Thomas Theuringer
+49-2103-29-11826
e-mail: pr@QIAGEN.com
SOURCE QIAGEN
Copyright 2017 PR Newswire
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024